This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Atreca Croissance future

Future contrôle des critères 0/6

Atreca devrait augmenter ses bénéfices de 4.3% par an. Le BPA devrait augmenter de 20.7% par an.

Informations clés

4.3%

Taux de croissance des bénéfices

20.7%

Taux de croissance du BPA

Biotechs croissance des bénéfices	28.5%
Taux de croissance des recettes	n/a
Rendement futur des capitaux propres	n/a
Couverture par les analystes	Low
Dernière mise à jour	31 May 2024

Mises à jour récentes de la croissance future

Recent updates

Prévisions de croissance des bénéfices et des revenus

OTCPK:BCEL - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	N/A	-52	N/A	N/A	1
12/31/2025	N/A	-48	N/A	N/A	1
12/31/2024	N/A	-38	N/A	N/A	1
12/31/2023	N/A	-65	N/A	N/A	1
9/30/2023	N/A	-98	-65	-65	N/A
6/30/2023	N/A	-85	-65	-64	N/A
3/31/2023	N/A	-93	-71	-70	N/A
12/31/2022	N/A	-97	-82	-81	N/A
9/30/2022	N/A	-105	-86	-81	N/A
6/30/2022	N/A	-110	-88	-81	N/A
3/31/2022	N/A	-108	-93	-69	N/A
12/31/2021	N/A	-109	-96	-61	N/A
9/30/2021	N/A	-103	-96	-63	N/A
6/30/2021	N/A	-98	-93	-62	N/A
3/31/2021	N/A	-92	-82	-66	N/A
12/31/2020	N/A	-86	-72	-67	N/A
9/30/2020	N/A	-83	-70	-65	N/A
6/30/2020	N/A	-76	-71	-65	N/A
3/31/2020	N/A	-74	-67	-63	N/A
12/31/2019	N/A	-67	-62	-59	N/A
9/30/2019	N/A	-59	-56	-53	N/A
6/30/2019	N/A	-53	-47	-45	N/A
3/31/2019	N/A	-44	-41	-40	N/A
12/31/2018	N/A	-38	-36	-35	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: BCEL devrait rester non rentable au cours des 3 prochaines années.

Bénéfices vs marché: BCEL devrait rester non rentable au cours des 3 prochaines années.

Croissance élevée des bénéfices: BCEL devrait rester non rentable au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Données insuffisantes pour déterminer si les revenus de BCEL devraient croître plus rapidement que le marché US.

Croissance élevée des revenus: BCEL ne devrait pas générer de revenus l'année prochaine.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de BCEL devrait être élevé dans 3 ans

This company listing is no longer active

Atreca Croissance future

Future contrôle des critères 0/6

Informations clés

Mises à jour récentes de la croissance future

Price target decreased by 24% to US$9.44

Price target increased to US$15.57

Price target decreased to US$16.63

Price target decreased to US$19.56

Price target decreased to US$25.33

Analysts update estimates

Recent updates

Atreca, Inc. Announces Resignation of Franklin Berger from the Board

Immunome, Inc. (NasdaqCM:IMNM) completed the acquisition of Substantially all Assets of Atreca, Inc. (NasdaqGS:BCEL).

Atreca, Inc. Files Form 15

Atreca, Inc.(OTCPK:BCEL) dropped from S&P TMI Index

Atreca, Inc.(OTCPK:BCEL) dropped from NASDAQ Composite Index

Atreca, Inc. Receives Written Notification from Nasdaq Regarding Minimum Bid Requirement

New major risk - Financial position

Atreca, Inc. Announces Board Resignations

Insufficient new directors

Atreca, Inc. Announces Resignation of Herbert Cross, Chief Financial Officer

Atreca Receives Notice from the Nasdaq Stock Market

Atreca, Inc. Reduces its Workforce by Approximately 40%

New major risk - Revenue and earnings growth

Here's Why We're A Bit Worried About Atreca's (NASDAQ:BCEL) Cash Burn Situation

Atreca, Inc. Presents Data from Ongoing Phase 1b Study of ATRC-101 in Patients with Select Advanced Solid Tumors During Oral Abstract

Insufficient new directors

Price target decreased by 24% to US$9.44

Atreca, Inc. Announces the Appointment of Philippe Bishop, MD, as Chief Medical Officer

Can Atreca (NASDAQ:BCEL) Afford To Invest In Growth?

Price target increased to US$15.57

Atreca GAAP EPS of -$0.72 misses by $0.02

Atreca, Inc.(NasdaqGS:BCEL) dropped from Russell 2500 Index

Here's Why We're A Bit Worried About Atreca's (NASDAQ:BCEL) Cash Burn Situation

Atreca Appoints Stephen Gould, Ph.D. as Chief Scientific Officer

Price target decreased to US$16.63

Atreca, Inc. Announces Publication in PNAS Mobilization of Innate and Adaptive Antitumor Immune Responses by the RNP-Targeting Antibody ATRC-101

Atreca: Biotech With Promise Based On First Candidate ATRC-101

Atreca, Inc. Provides an Update on Its Preclinical Pipeline in Oncology

Founder notifies of intention to sell stock

Is Atreca (NASDAQ:BCEL) In A Good Position To Invest In Growth?

Price target decreased to US$19.56

Atreca: Overvalued, Then Undervalued, Now Under Pressure - Making The Buy Case

Founder notifies of intention to sell stock

Atreca: Safety Data Brought Down Stock

Is Atreca (NASDAQ:BCEL) In A Good Position To Invest In Growth?

Price target decreased to US$25.33

Atreca, Inc.(NasdaqGS:BCEL) dropped from Russell 2500 Growth Index

We Think Atreca (NASDAQ:BCEL) Can Afford To Drive Business Growth

Chief Scientific Officer has left the company

Atreca, Inc Announces Executive Changes

Chief Business Officer has left the company

New 90-day low: US$13.00

Need To Know: Atreca, Inc. (NASDAQ:BCEL) Insiders Have Been Buying Shares

Co-Founder notifies of intention to sell stock

New 90-day high: US$15.82

We Think Atreca (NASDAQ:BCEL) Can Afford To Drive Business Growth

Atreca EPS misses by $0.06

Director notifies of intention to sell stock

New 90-day high: US$15.79

New 90-day low - US$12.67

Analysts update estimates

New 90-day low - US$14.63

Atreca, Inc. has completed a Follow-on Equity Offering in the amount of $125 million.

Prévisions de croissance des bénéfices et des revenus

Prévisions de croissance des analystes

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

Découvrir les entreprises en croissance